Weight Loss/Management

Unlock the Transformative Benefits of GLP-1 Medications

At Elysian Integrative Health and Wellness Group, your health and well-being are our highest priorities. Guided by the expertise of Dr. Erica Strother, we are proud to offer a comprehensive selection of GLP-1 receptor agonist medications, including semaglutide (Ozempic®, Wegovy®), dulaglutide (Trulicity®), and tirzepatide (Mounjaro®), to support your journey toward better weight management and metabolic health.

GLP-1 receptor agonists are innovative treatments that have demonstrated significant results in helping individuals manage type 2 diabetes and achieve sustainable weight loss. These medications work by helping to regulate appetite, slow gastric emptying, and maintain healthy blood sugar levels, making them powerful options for those seeking effective solutions for weight control or metabolic conditions.

Our dedicated team will partner with you to identify the most suitable GLP-1 medication for your unique health needs and goals. We are committed to delivering personalized care, expert guidance, and ongoing support every step of the way.

If you’re ready to explore the transformative benefits of GLP-1 medications, we invite you to contact our office or schedule an appointment online. Discover how Top Tier Health and Wellness Group can be your trusted ally on the path to a healthier, more vibrant life.

Regulate Appetite and Manage Cravings 

Our approach facilitates a significant reduction in appetite and cravings, empowering you to maintain your health goals without the persistent struggle against hunger. By incrementally adjusting medication levels, your body acclimates seamlessly, enabling you to make healthier dietary choices effortlessly and without experiencing a sense of deprivation.

Convenient Home Delivery

We streamline your weight loss journey by providing direct delivery of your medication, along with all essential supplies, right to your doorstep. This service eliminates the need for pharmacy visits and long wait times, offering you effortless and uninterrupted access to the treatment necessary for achieving your health goals.

Transform Your Health: Evidence-Based Weight Loss with GLP-1 Medications

Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as effective and safe options for the management of obesity and type 2 diabetes (Sinha et al., 2023). These medications work by enhancing satiety, reducing appetite, and promoting weight loss through effects on the central nervous system and gastrointestinal tract.

Recent studies have highlighted the significant weight loss achieved with GLP-1 receptor agonists:

• Semaglutide: In a randomized controlled trial, adults with overweight or obesity receiving semaglutide 2.4 mg once weekly achieved a mean weight loss of 14.9% of body weight at 68 weeks, compared to 2.4% with placebo (Wilding et al., 2021).

• Tirzepatide: As a dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, tirzepatide has demonstrated even greater efficacy. In the SURMOUNT-1 trial, participants treated with tirzepatide experienced a mean weight reduction ranging from 15.0% to 20.9% at 72 weeks, versus 3.1% in the placebo group (Jastreboff et al., 2022; Sinha et al., 2023).

The current evidence supports the use of GLP-1 receptor agonists as an effective strategy for weight management in individuals with obesity or type 2 diabetes, with the potential for significant and sustained weight loss (Sinha et al., 2023).

At Top Tier Health and Wellness Group, we are committed to utilizing the latest evidence-based therapies to support your long-term weight management and metabolic health.

References:

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Kushner, R. F. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387 (3), 205-216. https://doi.org/10.1056/NEJMoa2206038

Sinha, R., Papamargaritis, D., Sargeant, J. A., & Davies, M. J. (2023). Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. Journal of Obesity & Metabolic Syndrome, 32 (1), 25–45. https://doi.org/10.7570/jomes22067

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384 (11), 989-1002. https://doi.org/10.1056/NEJMoa2032183